CoChat
Sign Up
Cited by 122Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity, Physical Activity, Diet

Phentermine/Topiramate for the Treatment of Obesity

Smith, Steven M, Meyer, Melissa, Trinkley, Katy E·2013·Annals of Pharmacotherapy
DOI 10.1345/aph.1r501
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To review the pharmacology, efficacy, and safety of phentermine/topiramate (PHEN/TPM) in the management of obese patients. DATA SOURCES: MEDLINE (1966-July 2012) was searched using the terms weight loss, obesity, phentermine and topiramate, phentermine, topiramate, Qnexa, Qsymia, and VI-0521. Additionally, the new drug application and prescribing information for PHEN/TPM were retrieved. STUDY SELECTION/DATA EXTRACTION: All studies considering the pharmacology, efficacy, and safety of PHEN/TPM were reviewed with a focus on efficacy and safety data from Phase 3 trials. DATA SYNTHESIS: In 3 Phase 3 trials (EQUIP, CONQUER, and SEQUEL), treatment with PHEN/TPM consistently demonstrated statistically significant weight loss compared with placebo. After 56 weeks of treatment, percent weight loss achieved with PHEN/TPM was 10.6%, 8.4%, and 5.1% with 15/92 mg, 7.5/46 mg, and 3.75/23 mg, respectively (p < 0.0001). The 52-week extension study (SEQUEL) showed maintained weight loss over 2 years with 9.3% and 10.5% weight loss from baseline for 7.5/46 mg and 15/92 mg PHEN/TPM (p < 0.0001). A significantly higher proportion of patients achieved greater than 5%, 10%, or 15% weight loss with PHEN/TPM compared with placebo. Significant reductions in waist circumference, fasting triglycerides, and fasting glucoses were also attributable to PHEN/TPM. The drug was generally well tolerated in clinical trials. Adverse reactions occurring in 5% or more of study subjects included paresthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth. CONCLUSIONS: PHEN/TPM is a new, once-daily, controlled-release, combination weight-loss product approved as an adjunct to diet and exercise for chronic weight management of obese or overweight patients with weight-related comorbidities. PHEN/TPM is modestly effective and a viable option for patients interested in losing weight, although long-term safety data are lacking.

Integrity signals

Registry

Crossref · 10.1345/aph.1r501

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In SEQUEL, weight loss was maintained over 2 years at 9.3% and 10.5% from baseline for phentermine/topiramate ER 7.5/46 mg and 15/92 mg, respectively.

    “Weight loss was maintained over 2 years at 9.3% and 10.5% from the baseline for 7.5/46 and 15/92 mg doses of phentermine/topiramate ER, respectively [39].”

    From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [39]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Smith, S. M., Meyer, M., & Trinkley, K. E.
Affiliations
  • University of Colorado Anschutz (US)
  • Exempla Saint Joseph Hospital (US)
  • University of Colorado Denver (US)
Corresponding author
Trinkley, Katy E
ORCID
Venue
Annals of Pharmacotherapy
Publisher
SAGE Publications
Published
2013-03
Volume
47
Issue
3
Pages
340-349
ISSN
  • 0012-6578 (ISSN-L)
  • 1060-0280
  • 1542-6270
DOI
10.1345/aph.1r501
OpenAlex
W2145130242
Cited by
122
References
12
Citations by year
2026: 9 · 2025: 19 · 2024: 15 · 2023: 18 · 2022: 10 · 2021: 13 · 2020: 6 · 2019: 4 · 2018: 4 · 2017: 8 · 2016: 5 · 2015: 8 · 2014: 2 · 2013: 1
FWCI
3.92
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Annals of Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
phentermine/topiramate, obesity, weight loss, weight management, efficacy, drug safety, adverse effects, long-term weight maintenance, waist circumference, triglycerides, fasting blood glucose
MeSH terms
Topiramate, Drug Combinations, Fructose, Humans, Obesity, Phentermine, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review